Chulalongkorn doctors inform the good news, test the ‘ChulaCOV19’ vaccine in volunteers to accelerate the next phase of research.

August 17, 2021, Chulalongkorn Hospital, Thai Red Cross Society, Faculty of Medicine Chulalongkorn University and the Vaccine Research Center Faculty of Medicine Chulalongkorn University Joint press conference to inform the progress of the vaccination test “ChulaCov19” (Chula-Kov-Nine-Teen) type mRNA of Thai nationality of volunteers who passed the screening phase 1 that were healthy. Applicants have good immunity, highly stimulating antibodies to inhibit the original strain. and can inhibit cross-species infection in all 4 species, namely Alpha, Beta, Gamma and Delta.

<!–

–>

Prof. Dr. Suthipong Watcharasin, Director of Chulalongkorn Hospital, Thai Red Cross Society and Dean of the Faculty of Medicine Chulalongkorn University said that from the epidemic of coronavirus disease 2019 (COVID-19) in Thailand, Chulalongkorn Hospital, the Thai Red Cross Society and the Faculty of Medicine Chulalongkorn University Has prepared the facility, doctors, nurses, personnel, modern technology, standardized to be used for effective screening and treatment of people.

In addition, the vaccine research center Faculty of Medicine Chulalongkorn University which is a medical research institute that has been in collaboration with medical researchers and scientists both nationally and globally to come together to develop, research, develop, innovate, produce vaccines for use in preventing various diseases. The latest ChulaCov19 vaccine development phase 1 on June 14, 2021 was the first day of testing in healthy volunteers who passed the screening. along with follow-up Under close supervision from a team of medical professionals, it was found that all the volunteers in the first phase of testing have a very good level of immunity and is safe

It was a great pleasure. The development of the ChulaCov19 vaccine is possible with the goal. people gain confidence and ensure the highest safety of vaccination testing. However, thanks to the Ministry of Health National Vaccine Institute Vaccine Research Center Faculty of Medicine Chulalongkorn University and many other agencies, including the public, private and public sectors including medical researchers and scientists both nationally and globally who jointly develop research Continuing the invention of vaccine production including the development of the vaccine research center ChulaCov19 Faculty of Medicine Chulalongkorn University Until successful, it can produce and be ready to inject to volunteers in the next phase. This is a great pleasure. that will be used and create benefits and reputation for Thailand at the international level for sure

On the side of Prof. Dr. Kiat Rakrungtham Executive Director of the COVID-19 Vaccine Development Project Vaccine Research Center Faculty of Medicine Chulalongkorn University and Chulalongkorn Hospital, the Thai Red Cross Society, said that the development of ChulaCov19 vaccine has received support from the public, private and public sectors such as the National Vaccine Institute, the National Research Office (NRCT), the second century scholarship. Chulalongkorn University and donations from the Chulalongkorn University Medical Alumni Association Thai Red Cross Society Vaccine Research Donation Fund

ChulaCov19 vaccine is an invention, design and development by Thai people in collaboration with the world’s leading physician-scientist who invented this technology, Prof. Drew Weissman, University of Pennsylvania. The same commitment is to make mRNA vaccine technology more accessible to the majority of people, especially in middle- and low-income countries.

The ChulaCov19 vaccine is made from microscopic parts of the coronavirus’ genetic material. (Without the use of infection in any way), which when the body receives this tiny piece of genetic material. It builds up the spike protein and stimulates the immune system to fight the virus when it comes in contact with it. Once the mRNA vaccine has been activated by the body to make proteins, within 6 days the mRNA is destroyed without any accumulation in the body.

In the past, the vaccine research center Faculty of Medicine Chulalongkorn University The experiments in monkeys and mice were successful. It has been found that it can help stop the virus from entering the bloodstream and can create a high level of immunity. leading to production and stage clinical testing 1 to volunteers on Monday, June 14, 2021 as the first day, divided into the following tests:

– The test in Phase 1 was divided into two age groups of 72 people.

– The first group were volunteers aged 18-55 years who tested 36 people.

– The second group consisted of 36 volunteers aged 56-75 years.

The two groups above were divided into subgroups vaccinated with 10 mcg, 25 mcg and 50 mcg to see if the vaccine At what dosage is ChulaCov19 most effective? Because Moderna currently uses 100 micrograms of the vaccine and Pfizer uses 30 micrograms, the center has to study whether Thais or Asians.

Suitable for injection 10 or 25 or 50 micrograms to know the safe dose and highly stimulate the immune system. After that, 150-300 people will enter Phase 2 clinical trials. It is expected that injections can begin around August 2021 onwards.

It also informed the good news about the research and development of the ChulaCov19 vaccine that the results of the trial on June 14, 2021 of Phase I in 36 volunteers aged 18-55 and 36 groups. Between the ages of 56-75 years, it was found that after 7 days of the second injection, the side effects were mild to moderate, such as Pain at the injection site, fatigue, fever, chills, but the symptoms improve on average within 1-3 days. And from testing, ChulaCov19 has a high antibody stimulation, stimulating a very high antibodies to inhibit the original strain.

In addition, it can inhibit cross-infection of all 4 strains, namely Alpha, Beta, Gamma and Delta by more than 80%, as well as stimulate T-Cell immunity, which will help eliminate and control the pathogen in the cells of infected people. as well

Other advantages of the ChulaCov19 vaccine namely …

1. According to the temperature tolerance test of the vaccine, ChulaCov19 vaccine can be kept at refrigerator temperature (2-8°C) for up to 3 months and at room temperature (25°C) for 2 weeks. It is much easier to store than other brands of mRNA vaccine for COVID-19.

2. The results of animal testing were very good. From an experiment in a special type of rats designed to be able to develop COVID-19, it was found that when the rats received 2 ChulaCov19 vaccinations 3 weeks apart, the rats were then given the virus through the nose. It can prevent rats from getting sick and stop the virus from entering the bloodstream. It can also reduce the number of germs in the nose and lungs by at least 10,000,000 times. When tested for toxicity, it was found to be safe. Unvaccinated mice will develop symptoms of COVID-19 within 3-5 days, and all of them. The infection is high in the bloodstream, in the nose and lungs.

3. The mRNA type vaccine can be produced quickly. No need to wait for culture like some vaccines. But mRNA vaccines can be used to design vaccines by knowing the strain of the virus. Synthetic in vitro. Up to 4 weeks, the vaccine can be tested in rats. This fast production This eliminates the need for large factories. In addition, when a mutant is present, vaccines can be synthesized faster as well.

Finally, the vaccine research center Faculty of Medicine Chulalongkorn University Prepared to develop a second-generation vaccine with experimental animals in parallel with the first-generation model above. to support drug-resistant or mutated germs that the world is worried about, such as the British strain Indian breed South African species Brazilian strains, etc., all of which are vaccines invented. Developed and produced by Thai people from the cooperation of all sectors as well If all goes according to plan, it is expected that vaccines against vaccine-resistant mutants can be produced for testing in volunteers by the fourth quarter of this year.

The challenge for Thai people is that if we want at least one of the four vaccines currently being researched and developed, including that of the ChulaCov19 mRNA vaccine, to be registered and widely available before the Thai New Year next year, it is. April 2022 Thailand must have clear goals in 4 areas and must be driven seriously. Parallel to that is

1). There must be a system for raising funds from the public, private and public sectors with objectives and with sufficient funds and approval of the use of funds efficiently and quickly, with each key involved in meetings to discuss regularly. Not stuck in the traditional bureaucratic framework

2). The Food and Drug Administration or the FDA has expedited the determination of rules and regulations. Applying for registration of vaccines produced in Thailand thinks that people will need to do a lot of research or how to adhere to the criteria similar to that of Taiwan. Which must be urgently cleared by this September in order to be able to act quickly.

3). Thai vaccine factories, in the case of ChulaCov19 mRNA, are accelerating production so that vaccines can be tested in Phase II, B or Phase III subjects and escalate to millions of doses. for actual use in registration

4). The government must have a pre-purchase policy for vaccines to enable vaccine developers to have the budget to reserve purchase orders for raw materials that will take at least six months to complete if Thailand Committed, serious and effective, we believe that Thailand before Songkran next year must have at least one vaccine actually used for Thai people by Thai people.